Post-transplant diabetes (PTDM), a common diagnosis following kidney transplantation, is strongly associated with adverse outcomes and its pathophysiology is poorly understood. Adipose tissue produces multiple cytokines or adipokines involved in inflammation and glucose metabolism. In patients with chronic kidney disease (CKD), adipose tissue cytokine production is altered. We have shown that with loss of kidney function there is increased production of both inflammatory cytokines and adiponectin in adipose tissue with concurrent adiponectin resistance in peripheral muscle tissue. Our additional preliminary data indicate 1) TNF? levels are associated with PTDM, 2) patients who develop PTDM have increased mRNA expression of TNF? and lower adiponectin expression in visceral fat compared to those who do not develop PTDM, 3) in myoblast culture, TNF? blunts adiponectin derived glucose transport. Our theory is that adiponectin resistance plays a key role in impaired glucose uptake and insulin resistance in CKD. Moreover following kidney transplantation despite improvement in kidney function, there will be a residual imbalance in adiponectin resistance and adiponectin production among patients who develop PTDM. Our overall hypothesis for this study is that CKD mediated adipose tissue inflammation and ROS contribute to development of PTDM by promoting muscle and adipose tissue adiponectin resistance. Our study will investigate the role of inflammation and ROS on adiponectin resistance and also the adipose and muscle tissue metabolic phenotype of patients that develop PTDM in 2 aims: 1) To define mechanistic pathways by which uremia, inflammation and/or ROS promote adiponectin resistance in muscle and adipose cells we will; i) expose myocytes and adipocytes to uremia, inflammatory cytokines and ROS with and without adiponectin, ii) study adiponectin downstream effectors and function (glucose transport and ?-oxidation) following cytokine/uremia exposure, and iii) determine if an antioxidant/anti-inflammatory treatment mitigates adiponectin resistance in muscle/adipose cells exposed to cytokines/uremia. We will also conduct genetic modulation experiments by altering key proteins from the inflammatory pathway and antioxidant regulators in order to determine if we can reverse the metabolic phenotype induced by cytokine/uremia exposure; 2) To determine the phenotype of adipose and muscle tissue in patients that develop PTDM, we will i) study macrophage infiltration, ROS, and ER stress in adipose tissue of patients that develop PTDM compared to patients that do not, ii) study the metabolic profile of adipose tissue from PTDM patients, and iii)study muscle mitochondrial function and adiponectin pathway in patients that develop PTDM compared to patients that do not . This project will develop data to fill gaps in knowledge on tissue metabolic changes in CKD that influence glucose regulation and on dysregulatory mechanisms that contribute to PTDM. Insights gained from this study will facilitate subsequent research on novel therapeutic strategies to ameliorate metabolic complications post-kidney transplant.

Public Health Relevance

Post-transplant diabetes is both common and associated with significant graft loss and patient morbidity and mortality. Because the mechanism and role of adipose derived inflammation and oxidative stress in glucose regulation post-kidney transplant has not been characterized, we propose a series of studies including tissue studies from ESRD patients, with post-transplant follow-up, paired with in-vitro experiments to examine the mechanism by which inflammation and/or oxidative stress promotes adiponectin resistance, to determine the adipose and muscle tissue phenotype of patients that develop PTDM. Studies to determine the role of adipose tissue inflammation and muscle metabolism on the development of PTDM will provide insights into the pathophysiology of PTDM and will open new avenues of research to identify novel biomarkers and potential therapeutic targets for PTDM.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK111574-01A1
Application #
9382106
Study Section
Pathobiology of Kidney Disease Study Section (PBKD)
Program Officer
Abraham, Kristin M
Project Start
2017-07-21
Project End
2022-05-31
Budget Start
2017-07-21
Budget End
2018-05-31
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Thomas Jefferson University
Department
Type
Schools of Medicine
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107